Lyndra Therapeutics

At the recent Fierce Pharma Forward event, our Chief Medical Officer and President of Global Product Development Richard Scranton MD MPH spoke on a panel about advances and challenges in developing long-acting drug delivery platforms. This clip from his panel discussion underscores the critical need for novel drug delivery options, like the LYNX® platform, for patient care and outcomes. If you missed the live event, you can still register to stream the event on demand and learn more about the future of drug delivery and the work we’re doing at Lyndra: https://lnkd.in/e4BFEJHv

Our Senior Director of Workplace Operations & Safety, Divya Krishnamurthy, Ph.D., recently spoke with Lab Manager to share some of her experiences and insights on lab safety. Check out the full article here: https://lnkd.in/e9wM45Qj

This week, our Vice President of Engineering & Industrialization, Matt Peterson, spoke at the Next Gen Peptide Formulation & Delivery Summit in Boston. Matt presented on Journey of Challenges: Where Are Peptides Metabolized & How Can We Stop This? More details about the conference can be found here: https://lnkd.in/e7pYbmqW

Our President & CEO, Jessica Ballinger, will be joining an esteemed panel of industry leaders to discuss the Ecosystem of External Innovation at the Longwood Healthcare Leaders Spring MIT conference, June 18th, 2024. For More Information visit: https://lnkd.in/exxKDits #longwoodhealthcareleaders

This June, we proudly celebrate Pride Month and stand in solidarity with the LGBTQIA+ community. At Lyndra, Valuing Every Voice is one of our core values. We believe that everyone deserves to be their authentic selves, and we are committed to fostering an environment where all individuals feel seen, heard, and respected. We encourage our employees, partners, and followers to join us in supporting and celebrating diversity in all its forms. Together, we can create a more inclusive and equitable world. Happy Pride Month! 🌈 #PrideMonth #LGBTQIA #Inclusion #Diversity #Pride2024 #LoveIsLove

We are thrilled to see Jessica Ballinger share her expertise with Life Science Cares Boston  

Thank you Fierce Pharma for inviting Lyndra’s Chief Medical Officer and President of Global Product Development Richard Scranton MD MPH Scranton to be part of the inaugural Fierce Pharma Forward: Drug Development Insights event. There is a lot of innovation taking place in drug delivery and it was an honor to be part of this crucial conversation about how we can better deliver the medicines people need to treat their medical conditions and live healthier lives.   If you tuned into the talks, you will have been reminded that patients are the center of our work at Lyndra. As a former internist, Rich shared that, in his experience, it was often difficult to create better outcomes for patients who struggled to adhere to complex medication regimens.   “At Lyndra, we aim to remove some of the limitations of how medications are delivered today… Our mission is to improve upon what we had hoped daily medications would be. We believe [the LYNX® platform] is an elegant solution for a complex problem.”   Thank you to the Fierce Pharma team, Fraiser Kansteiner and Zoey Becker for inviting us! You can register for free and view the webinar here: https://lnkd.in/dn4M-PHU. 

Our Chief Medical Officer and President of Global Product Development Dr. Richard Scranton MD MPH will be speaking at Fierce Pharma Forward: Drug Development and Delivery Insights for 2024 on May 30th in two sessions: -“Industry Leaders: The State of the Drug Delivery Market,” a discussion with Zoey Becker - “Advances and Challenges in Developing Ultra-Long-Acting Drug Delivery Platforms Panel,” moderated by Fraiser Kansteiner, to be joined by Eran Harary, SVP, Clinical Development, Innovative Medicines R&D at Teva Pharmaceuticals; Daria Hazuda, Head of Infectious Disease and Vaccines Research at Generate:Biomedicines; Sherene Min, VP, Head of Global Clinical Development at ViiV Healthcare Register for the free virtual event to learn more about the work we’re doing at Lyndra to develop long-acting oral therapies: https://lnkd.in/dn4M-PHU   #DrugDelivery #Innovation #Biotech Fierce Life Sciences Events

Our President and Chief Executive Officer Jessica Ballinger Ballinger recently shared insights with Investment Reports on the potential impacts of our LYNX® drug delivery and plans for future partnerships with leading pharma companies in clinical research, manufacturing and commercialization. “Lyndra's LYNX drug delivery platform is the first long-acting oral platform that is not bound by the chemistry of the medicine. This means it has the potential to significantly transform the patient experience by…not only enhanc(ing) patient compliance by reducing dosing frequency but also minimiz(ing) the variability in drug levels, improving overall treatment efficacy and patient outcomes.” Read the full interview here: https://lnkd.in/ehWWGB_F #drugdelivery #biotech #innovation

Our Chief Technology Officer Kyle Haraldsen shared insights with European Pharmaceutical Review on emerging trends in drug delivery, including Lyndra’s work developing long-acting oral therapies. “…We need to make sure we’re creating things that patients actually want – being truly patient-centric... This is why we’re focused on developing long-acting oral medicines at Lyndra. It’s a drug delivery method that patients know and like, and the potential benefits of long-acting medicines are clear: they can reduce patient and caregiver burden, increase medication adherence and, in turn, produce better patient outcomes.” Read the full interview here: https://lnkd.in/ea6xT-UY #drugdelivery #innovation #biotech